140 µm
thin struts

Clinically proven

Tri-axial delivery
system

Technical data /
ordering info

Teleflex™
Empowering the future of healthcare

Pulsar™-35

Self-Expanding Stent System





Pulsar™-35 Stent

Clinically proven thin struts stent with tri-axial delivery system.

140 µm thin struts – thinner than the leading brands[1]

Thinner struts for low chronic outward force (COF)[2]



Thinner struts and lower COF make a difference:*
- Lower risk of restenosis[3]
- Reduced vessel injury and inflammation[3]
- Faster endothelialization[4,5]

Vessel response on SE stent 1 mm oversizing showing neotintimal hyperplasia at 90 days[6]*



Pulsar™ Stent
Teleflex
Low COF



LifeStent™ XL
BD
High COF

**As demonstrated in pre-clinical studies*

Stent strut thickness in perspective[1]



Clinically proven

Long term safety and efficacy (24-month data)

Clinically proven even in calcified lesions (4EVER), total occlusions (TASC D) and in all-comers registry (BIOFLEX PEACE).¤

		12 MONTHS		24 MONTHS	
	A.L.L††	PP†	FTLR**	PP†	FTLR**
ALL-COMERS BIOFLEX PEACE[7] (stent only)	8.2 cm	84.7 %	89.3 %	78.4 %	89.3 %
4F INTERVENTIONS 4EVER[8]	7.1 cm	81.4 %	89.3 %	72.3 %	82.7 %
LONG & OCCLUDED TASC D[9]	24.5 cm	77.0 %	86.0 %	–	–

¤Clinical outcomes of Pulsar™-18 stent can be used to illustrate clinical outcomes of Pulsar™-35 stent due to identical stent platforms

89.3 %
24-month FTLR
BIOFLEX PEACE

Sufficient radial force for a long term vessel support, even in calcified lesions



After the treatment 2011 (Courtesy of Prof. van den Berg[10])

2016

Accurate stent deployment

Tri-axial delivery system

The outer shaft isolates the retractable shaft from friction caused by the introducer valve to ensure accurate stent deployment.



Easy release handle

One-handed stent release handle, ergonomically designed for a comfortable and stable handling.



** *FTLR–Freedom from Target Lesion Revascularization*
† *PP–Primary Patency*
†† *A.L.L.–Average Lesion Length*

Pulsar™-35 Stent

Vascular Intervention Peripheral

Indicated for use in patients with atherosclerotic disease of the femoral and proximal popliteal arteries, in particular for the treatment of insufficient results after percutaneous transluminal angioplasty (PTA).*

Technical data

STENT	
Catheter type	OTW
Recommended guide wire	0.035”
Stent material	Nitinol
Strut thickness	140 µm
Strut width	85 µm
Stent coating	**proBIO**™ (Amorphous Silicon Carbide)
Stent markers	6 gold markers each end
Sizes	ø 5.0–7.0 mm; L: 30–200 mm
Proximal shaft	6F, hydrophobic coating
Usable length	90 and 135 cm

Ordering Information

	STENT Ø	CATHETER LENGTH 90 CM; STENT LENGTH								
		20 mm	**40 mm**	**60 mm**	**80 mm**	**100 mm**	**120 mm**	**150 mm**	**170 mm**	**200 mm**
	5.0 mm	379878	379879	379880	379881	379917	379918	379919	379920	379921
6F	**6.0 mm**	379883	379884	379885	379886	379922	379923	379924	379925	379926
	7.0 mm	379888	379889	379890	379891	379927	379928	379929	379930	379931

	STENT Ø	CATHETER LENGTH 135 CM; STENT LENGTH								
		20 mm	**40 mm**	**60 mm**	**80 mm**	**100 mm**	**120 mm**	**150 mm**	**170 mm**	**200 mm**
	5.0 mm	379898	379899	379900	379901	379937	379938	379939	379940	379941
6F	**6.0 mm**	379903	379904	379905	379906	379942	379943	379944	379945	379946
	7.0 mm	379908	379909	379910	379911	379947	379948	379949	379950	379951

** Indication as per IFU.*

References:

1 Data on file. 6.0 mm diameters.
2 Data on file. 6.0 mm diameters. Supera stent not possible to test due to its design and applied test method.
3 Zhao HQ Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc. Interv. Radiol. 2009; 32(4); 720-6.
4 Koskinas C. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. JACC 2012 10;59(15):1337-49.
5 Koppara T. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv. 2015 8(6):e002427.
6 Funovics M. Correlation between chronic outward force (COF) and neointimal hyperplasia in self-expanding nitinol stents in swine in clinically relevant oversizing ranges. Presented at: LINC, Jan 26, 2017; Leipzig, Germany.
7 Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions–the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301-1526a000785.
8 Bosiers M et al. 4-French–compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive disease: Results of the 4EVER Trial. ENDOVASC THER 2013; 20: 746-756.
9 Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 ; 54(4):433-9.
10 Data on file.

Leading competitors have been selected based on the PV Stent Revenue Market Shares EU (2017) and PV Revenue Market Shares APAC (2015) (Source: Millennium Research Group Inc.). Latest SFA self-expanding stents for each manufacturer.

398938-EN · REV G · 10 25 PDF · DV

Distributed by:
Teleflex Headquarters International, Ireland · Teleflex Medical Europe Ltd. · IDA Business & Technology Park
Dublin Road · Athlone · Co Westmeath · Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · orders.intl@teleflex.com
United Kingdom Tel. +44 (0)14 94 53 27 61 · info.uk@teleflex.com
South Africa Tel. +27 (0)11 807 4887 · assist.africa@teleflex.com

teleflex.com

Teleflex™
Empowering the future of healthcare